PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review

被引:0
作者
Elisabeth Specht Stovgaard
Anne Dyhl-Polk
Anne Roslind
Eva Balslev
Dorte Nielsen
机构
[1] University of Copenhagen,Dept. of Pathology, Herlev and Gentofte Hospital
[2] University of Copenhagen,Dept. of Oncology, Herlev and Gentofte Hospital
来源
Breast Cancer Research and Treatment | 2019年 / 174卷
关键词
Breast cancer; PD-L1; Biomarker; Prognostic; Immunohistochemistry;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:571 / 584
页数:13
相关论文
共 201 条
[41]  
Jensen K(2016)Prognostic implications of tumor-infiltrating lymphocytes in association with programmed death ligand 1 expression in early-stage breast cancer Clin Breast Cancer 108 81-370
[42]  
Keir ME(2016)PD-L1 Expression Is associated with tumor FOXP3(+) regulatory T-cell Infiltration of breast cancer and poor prognosis of patient J Cancer 70 255-1179
[43]  
Butte MJ(2017)Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer Cancer Sci 8 51641-292
[44]  
Freeman GJ(2017)Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1 (2017) J Clin Pathol 70 860-342
[45]  
Cimino-Mathews A(2017)PD-L1 and intratumoral immune response in breast cancer Oncotarget 7 11671-619
[46]  
Thompson E(2017)Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer J Clin Pathol 2 16002-1331
[47]  
Taube JM(2017)Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value Sci Rep 5 805-133
[48]  
Pardoll DM(2016)Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer NPJ breast cancer 34 2460-e244
[49]  
Ribas A(2016)PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker Springerplus 31 288-3876
[50]  
Hu-Lieskovan S(2016)Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study J Clin Oncol 2 361-538